Taken together, these data show that pharmacologic inhibition of ABCC1 sensitizes AML cells towards BH3-mimetic drugs targeting BCL-2/BCL-xL/BCL-w. This evidence concerns the gene BCL2L1 and acute myeloid leukemia.